Search

Displaying results 3311 - 3320 of 8517 in total
  1. Drug

    Paricalcitol

    go.drugbank.com/drugs/DB00910
    ApprovedInvestigational

    Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure.

  2. Drug

    Collagen-polyvinylpyrrolidone

    go.drugbank.com/drugs/DB16525
    Investigational

    Collagen-polyvinylpyrrolidone is a copolymer generated from a mixture of type I collagen and low-molecular-weight PVP that has undergone γ irradiation[A227733].

  3. Drug

    Imiglucerase

    go.drugbank.com/drugs/DB00053
    ApprovedInvestigational

    Human Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human ...

  4. Drug

    BMS-188797

    go.drugbank.com/drugs/DB12619
    Investigational

    BMS-188797 has been used in trials studying the treatment of Unspecified Adult Solid Tumor, Protocol Specific.

  5. Drug

    Pegademase

    go.drugbank.com/drugs/DB00061
    ApprovedWithdrawn

    Bovine adenosine deaminase derived from bovine intestine that has been extensively pegylated for extended serum half life.

  6. Drug

    Oxyphenbutazone

    go.drugbank.com/drugs/DB03585
    ApprovedWithdrawn

    Oxyphenbutazone was withdrawn from the Canadian market in March 1985 due to concerns regarding bone marrow suppression.

  7. Drug

    Ethanolamine oleate

    go.drugbank.com/drugs/DB06689
    Approved

    Ethanolamine oleate is a mild sclerosing agent. It is composed of ethanolamine, a basic substance, which when combined with oleic acid forms a clear, straw to pale yellow colored, deliquescent oleate.

  8. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    As of August 2007 elacridar was not listed on GSK's product pipeline. Development is assumed to have been discontinued.

  9. Drug

    Dexlansoprazole

    go.drugbank.com/drugs/DB05351
    Approved

    release system: This aims to address some limitations of the older-generation PPIs, such as short plasma half-life and the need for meal-associated dosing. … Compared to the older generation of PPIs (which includes [DB00213], [DB00338], and [DB00448]),[A178084] dexlansoprazole has a unique pharmacokinetic profile due to its delayed-release and dual-delivery

  10. Drug

    NS-398

    go.drugbank.com/drugs/DB14060
    Experimental

    It was developed as part of the mechanistic study of the cyclooxygenases.